Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach.
Dyslipidemia is an established cardiovascular risk factor in the general population. However, in patients suffering from chronic kidney disease (CKD) this relationship is less clear, and many studies show that low, rather than high, cholesterol levels predict mortality in this patient population. This review presents an overview of the major disorders of lipid metabolism in the course of CKD and their clinical implications. We also discuss the role of genetic determinants predisposing to dyslipidemia, as well as current therapeutic approaches. Finally, the mendelian randomization approach as a novel tool to elucidate the seemingly paradoxical association between hypercholesterolemia and mortality in CKD will be discussed.
Chmielewski
Michal
M
Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm - Sweden.
Carrero
Juan Jesus
JJ
Nordfors
Louise
L
Lindholm
Bengt
B
Stenvinkel
Peter
P
D002908:Chronic Disease; D050171:Dyslipidemias / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications* / Q000378:metabolism; D050356:Lipid Metabolism; D040242:Risk Reduction Behavior
D000960:Hypolipidemic Agents